HomeHealthcare & Life SciencesPharmaceuticals Atypical Hemolytic Uremic Syndrome Treatment Market

South Korea Atypical Hemolytic Uremic Syndrome Treatment Market Size & Outlook, 2026-2034


South Korea Atypical Hemolytic Uremic Syndrome Treatment Market Insights

  • According to Reed Intelligence analysis, the South Korea Atypical Hemolytic Uremic Syndrome Treatment Market size was USD 47.67 Million in 2025 and is projected to reach USD 122.91 Million by 2034.
  • The South Korea market is projected to grow at a CAGR of 11.12% between 2026 and 2034.
  • By segment, Complement Inhibitors emerged as the largest Drug Class in terms of market size in 2025.
  • Gene Therapy is anticipated to remain the most attractive Drug Class segment, recording the fastest growth during the forecast period.

Other Key Findings


  • As of 2025, South Korea held 1.4% of the global Atypical Hemolytic Uremic Syndrome Treatment Market size.
  • By 2034, United States is anticipated to capture the largest share of the global Atypical Hemolytic Uremic Syndrome Treatment Market.
  • In Asia Pacific, China is expected to lead the regional Atypical Hemolytic Uremic Syndrome Treatment Market size by 2034.
  • Taiwan will remain the fastest-growing market in Asia Pacific, reaching USD 88.28 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 47.67 Million
Market Size In 2034 USD 122.91 Million
Largest segment Complement Inhibitors
Units Revenue in USD Million
CAGR 11.12% (2026-2034)
Segmnetation Covered
Drug Class
  1. Complement Inhibitors
  2. Immunosuppressants
  3. Gene Therapy
Treatment Type
  1. First-Line Therapy
  2. Second-Line Therapy
Route of Administration
  1. Intravenous
  2. Subcutaneous
End-Use
  1. Hospitals
  2. Specialty Clinics
  3. Others
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports